RXDX - Prometheus initiates mid-stage PRA023 ulcerative colitis trial

Prometheus Biosciences (RXDX) announces the initiation of the Phase 2 ARTEMIS-UC trial evaluating PRA023 for moderate-to-severe ulcerative colitis ((UC)).The company highlighted that the Phase 2a initiation in Crohn’s Disease ((CD)) on track for the third-quarter of 2021.Prometheus recently completed the dosing phase of the early-stage trial of PRA023 to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of the treatment in healthy volunteers.Final Phase 1a results of PRA023 in UC and CD are expected in the fourth quarter of 2021, the company said.

For further details see:

Prometheus initiates mid-stage PRA023 ulcerative colitis trial